Primary leiomyosarcoma of the uterine cervix: an unusual case and critical appraisal.

Cervix cervical cancer cervical sarcoma leiomyosarcoma sarcoma uterine sarcoma uterus

Journal

Journal of surgical case reports
ISSN: 2042-8812
Titre abrégé: J Surg Case Rep
Pays: England
ID NLM: 101560169

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 28 06 2023
accepted: 15 07 2023
medline: 7 8 2023
pubmed: 7 8 2023
entrez: 7 8 2023
Statut: epublish

Résumé

Leiomyosarcomas of the uterine cervix are rare, mostly occurring in perimenopausal women. Diagnosis is based on pathology and immunohistochemistry. Surgery with a total abdominal hysterectomy and bilateral salpingo-oophorectomy remains the standard. A female patient in her 60s presented with heavy postmenopausal bleeding. Vaginal ultrasound scan and magnetic resonance imaging showed a large strongly vascularized cervical mass with features suspicious of sarcomatous degeneration. Positron Emission Tomography-Computed Tomography (PET-CT) did not reveal any evidence of metastases nor lymphadenopathy, but presence of right hydronephrosis. An abdominal hysterectomy with bilateral salpingo-oophorectomy, and end-to-end anastomosis of the right ureter, was performed. Pathology showed an International Federation of Gynecology and Obstetrics (FIGO)-stage 1B leiomyosarcoma of the uterine cervix. No adjuvant treatment was given. Adjuvant radiotherapy reduces the risk of recurrence but no survival impact. The benefit of adjuvant chemotherapy is questionable given the lack of randomized trials. Multidisciplinary research concerning molecular alterations of the disease is required to determine optimal management strategies with potential novel molecular therapies.

Identifiants

pubmed: 37545785
doi: 10.1093/jscr/rjad439
pii: rjad439
pmc: PMC10401315
doi:

Types de publication

Case Reports

Langues

eng

Pagination

rjad439

Informations de copyright

Published by Oxford University Press and JSCR Publishing Ltd. © The Author(s) 2023.

Déclaration de conflit d'intérêts

None declared.

Références

J Gynecol Oncol. 2020 May;31(3):e25
pubmed: 31912680
Gynecol Oncol. 2017 Apr;145(1):208-216
pubmed: 28209496
J Clin Oncol. 2018 Oct 5;:JCO1800454
pubmed: 30289732
BMJ Case Rep. 2013 Mar 20;2013:
pubmed: 23519508
J Clin Ultrasound. 2007 Oct;35(8):449-57
pubmed: 17636502
Diagn Interv Imaging. 2013 Dec;94(12):1291-8
pubmed: 24183708
Front Oncol. 2023 Mar 08;13:1149106
pubmed: 36969049
Oncotarget. 2019 Apr 2;10(26):2561-2575
pubmed: 31069017
Acta Oncol. 1990;29(2):185-91
pubmed: 2334571
Gynecol Oncol. 2003 Dec;91(3):636-42
pubmed: 14675691
Gynecol Oncol. 2003 Jun;89(3):460-9
pubmed: 12798712
Springerplus. 2014 Nov 18;3:678
pubmed: 25520907
Gynecol Oncol. 1996 Aug;62(2):226-9
pubmed: 8751554

Auteurs

Ines Lebbe (I)

Department of Gynecology and Gynecological Oncology, AZ Sint-Jan Hospital Bruges, Bruges, Belgium.

Eveline De Cuypere (E)

Department of Medical Oncology, AZ Sint-Jan Hospital Bruges, Bruges, Belgium.

Nele Claes (N)

Department of Medical Oncology, AZ Sint-Jan Hospital Bruges, Bruges, Belgium.

Anne Loccufier (A)

Department of Gynecology and Gynecological Oncology, AZ Sint-Jan Hospital Bruges, Bruges, Belgium.

Christophe Ghysel (C)

Department of Urology, AZ Sint-Jan Hospital Bruges, Bruges, Belgium.

Philippe Van Trappen (P)

Department of Gynecology and Gynecological Oncology, AZ Sint-Jan Hospital Bruges, Bruges, Belgium.

Classifications MeSH